CN1049223C - 改进的脑膜炎双球菌多糖结合菌苗 - Google Patents

改进的脑膜炎双球菌多糖结合菌苗 Download PDF

Info

Publication number
CN1049223C
CN1049223C CN90110444A CN90110444A CN1049223C CN 1049223 C CN1049223 C CN 1049223C CN 90110444 A CN90110444 A CN 90110444A CN 90110444 A CN90110444 A CN 90110444A CN 1049223 C CN1049223 C CN 1049223C
Authority
CN
China
Prior art keywords
gbmp
polysaccharide
binding substances
positive
acyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN90110444A
Other languages
English (en)
Chinese (zh)
Other versions
CN1055541A (zh
Inventor
哈罗德·J·詹宁斯
弗朗西斯·米琼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of CN1055541A publication Critical patent/CN1055541A/zh
Application granted granted Critical
Publication of CN1049223C publication Critical patent/CN1049223C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CN90110444A 1989-12-14 1990-12-14 改进的脑膜炎双球菌多糖结合菌苗 Expired - Fee Related CN1049223C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44819589A 1989-12-14 1989-12-14
US07/448,195 1989-12-14

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN93114763A Division CN1036522C (zh) 1989-12-14 1993-11-22 改进大肠杆菌k1夹膜多糖的制备方法
CN93114764A Division CN1072506C (zh) 1989-12-14 1993-11-22 改进的脑膜炎双球菌多糖结合菌苗
CN93119467A Division CN1036504C (zh) 1989-12-14 1993-11-22 改进脑膜炎双球菌b血清群多糖的抗原结合物的制备方法

Publications (2)

Publication Number Publication Date
CN1055541A CN1055541A (zh) 1991-10-23
CN1049223C true CN1049223C (zh) 2000-02-09

Family

ID=23779371

Family Applications (4)

Application Number Title Priority Date Filing Date
CN90110444A Expired - Fee Related CN1049223C (zh) 1989-12-14 1990-12-14 改进的脑膜炎双球菌多糖结合菌苗
CN93114764A Expired - Fee Related CN1072506C (zh) 1989-12-14 1993-11-22 改进的脑膜炎双球菌多糖结合菌苗
CN93119467A Expired - Fee Related CN1036504C (zh) 1989-12-14 1993-11-22 改进脑膜炎双球菌b血清群多糖的抗原结合物的制备方法
CN93114763A Expired - Fee Related CN1036522C (zh) 1989-12-14 1993-11-22 改进大肠杆菌k1夹膜多糖的制备方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN93114764A Expired - Fee Related CN1072506C (zh) 1989-12-14 1993-11-22 改进的脑膜炎双球菌多糖结合菌苗
CN93119467A Expired - Fee Related CN1036504C (zh) 1989-12-14 1993-11-22 改进脑膜炎双球菌b血清群多糖的抗原结合物的制备方法
CN93114763A Expired - Fee Related CN1036522C (zh) 1989-12-14 1993-11-22 改进大肠杆菌k1夹膜多糖的制备方法

Country Status (30)

Country Link
US (3) US5576002A (enExample)
EP (1) EP0504202B1 (enExample)
JP (1) JP2637845B2 (enExample)
KR (1) KR0158436B1 (enExample)
CN (4) CN1049223C (enExample)
AR (1) AR243934A1 (enExample)
AT (1) ATE121947T1 (enExample)
AU (1) AU641715B2 (enExample)
BR (1) BR9007917A (enExample)
CA (1) CA2071811C (enExample)
CZ (1) CZ283530B6 (enExample)
DE (1) DE69019164T2 (enExample)
DK (1) DK0504202T3 (enExample)
ES (1) ES2071288T3 (enExample)
FI (2) FI104539B (enExample)
HR (1) HRP920872A2 (enExample)
HU (2) HU9201966D0 (enExample)
IE (1) IE68414B1 (enExample)
IL (1) IL96676A (enExample)
IN (1) IN171747B (enExample)
NO (2) NO305275B1 (enExample)
NZ (1) NZ236471A (enExample)
PH (1) PH30305A (enExample)
PL (2) PL166035B1 (enExample)
RO (1) RO111416B1 (enExample)
RU (1) RU2105568C1 (enExample)
SI (1) SI20008B (enExample)
WO (1) WO1991008772A1 (enExample)
YU (1) YU24391A (enExample)
ZA (1) ZA9010065B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648241A (en) * 1989-09-15 1997-07-15 The General Hospital Corporation Conjugate vaccine against group B streptococcus
ATE121947T1 (de) * 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.
AU690525B2 (en) * 1992-09-24 1998-04-30 Brigham And Women's Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5700787A (en) * 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
AU695720B2 (en) * 1995-06-07 1998-08-20 Smithkline Beecham Biologicals (Sa) Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
ZA97248B (en) * 1996-01-18 1997-07-18 Rohm & Haas Method for identifying and quantifying polymers utilizing immunoassay techniques
US6048527A (en) * 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
EP0939647B2 (en) † 1996-08-27 2006-07-12 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
US6426074B1 (en) * 1997-03-19 2002-07-30 The Brigham And Women's Hospital Inc. Group B Streptococcus vaccine
EP0994723A1 (en) 1997-06-24 2000-04-26 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
DK1007546T3 (da) * 1997-08-27 2009-03-16 Novartis Vaccines & Diagnostic Molekylære mimetika af meningokok-B-epitoper
WO1999032653A1 (en) 1997-12-23 1999-07-01 North American Vaccine, Inc. Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugates vaccines
PL346645A1 (en) * 1998-08-19 2002-02-25 North American Vaccine IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
KR100704826B1 (ko) * 1998-08-19 2007-04-09 박스터 헬쓰케어 에스.에이. Ｎ-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트
US6436653B1 (en) 1998-12-15 2002-08-20 Exiqon A/S Method for introduction of reporter groups into bacterial lipopolysaccharide-derived carbohydrates and the subsequent coupling of such derivatives onto solid surfaces
US7083777B1 (en) * 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
US6518037B2 (en) * 1999-11-12 2003-02-11 University Of Iowa Research Foundation Two-component system that controls bacterial membrane synthesis
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
GB0011108D0 (en) * 2000-05-08 2000-06-28 Microscience Ltd Virulence gene and protein and their use
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
DE60235155D1 (de) 2001-04-17 2010-03-11 Childrens Hosp Oak Res Inst Monoklonale antikörper gegen molekulare mimetika von meningokokken-b-epitopen
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
HUE030532T2 (en) * 2002-03-26 2017-05-29 Glaxosmithkline Biologicals Sa Modified saccharides with improved stability in water for use as medicaments
CN1684707B (zh) * 2002-05-14 2012-09-05 诺华疫苗和诊断有限公司 用于细菌性脑膜炎的粘膜结合疫苗
RU2494758C2 (ru) * 2002-08-02 2013-10-10 ГлаксоСмитКлайн Байолоджикалз с.а. Нейссериальные вакцинные композиции, содержащие комбинацию антигенов
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
EP1638581A2 (en) * 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Zwitterionic immunomodulators for the treatment of asthma and allergy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
RU2333223C2 (ru) * 2003-08-12 2008-09-10 Лайпоксен Текнолоджиз Лимитед Альдегидные производные сиаловой кислоты, способы их получения, конъюгаты альдегидных производных сиаловой кислоты и фармацевтическая композиция на их основе
JP2008509886A (ja) 2004-06-23 2008-04-03 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 多糖誘導体および免疫応答の誘導における用途
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
WO2007000342A2 (en) 2005-06-27 2007-01-04 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
EP1872791A1 (en) 2006-06-30 2008-01-02 Institut Pasteur Use of bacterial polysaccharides for biofilm inhibition
WO2008157590A1 (en) * 2007-06-20 2008-12-24 Baxter International Inc. Modified polysaccharides for conjugate vaccines
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducción de respuestas inmunes
US9050283B2 (en) 2009-01-16 2015-06-09 University Of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal Salmonella
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有ｐｓａ組成物、その単離の方法および使用の方法
EP2752403A1 (de) * 2013-01-08 2014-07-09 Sika Technology AG Amin für emissionsarme Epoxidharz-Produkte
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
WO2018142280A2 (en) * 2017-01-31 2018-08-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ATE121947T1 (de) * 1989-12-14 1995-05-15 Ca Nat Research Council Verbessertes meningokokkale polysaccharidkonjugatvakzin.

Also Published As

Publication number Publication date
BR9007917A (pt) 1992-10-20
FI19991917L (fi) 1999-09-09
JP2637845B2 (ja) 1997-08-06
PL166659B1 (pl) 1995-06-30
CZ628490A3 (en) 1997-12-17
NO922316L (no) 1992-08-14
EP0504202B1 (en) 1995-05-03
CN1100656A (zh) 1995-03-29
JPH05505392A (ja) 1993-08-12
CN1100428A (zh) 1995-03-22
NO973311D0 (no) 1997-07-17
SI20008B (en) 2001-02-28
NO922316D0 (no) 1992-06-12
DE69019164D1 (de) 1995-06-08
HU9201966D0 (en) 1992-10-28
IE904513A1 (en) 1991-06-19
PH30305A (en) 1997-02-20
RU2105568C1 (ru) 1998-02-27
IL96676A0 (en) 1991-09-16
NZ236471A (en) 1992-10-28
IN171747B (enExample) 1992-12-26
CN1072506C (zh) 2001-10-10
FI922737A0 (fi) 1992-06-12
HU218146B (hu) 2000-06-28
FI104539B (fi) 2000-02-29
AR243934A1 (es) 1993-09-30
AU641715B2 (en) 1993-09-30
YU24391A (sh) 1995-12-04
RO111416B1 (ro) 1996-10-31
US5576002A (en) 1996-11-19
AU6898791A (en) 1991-07-18
CZ283530B6 (cs) 1998-04-15
ES2071288T3 (es) 1995-06-16
EP0504202A1 (en) 1992-09-23
WO1991008772A1 (en) 1991-06-27
CN1036522C (zh) 1997-11-26
US5902586A (en) 1999-05-11
DK0504202T3 (da) 1995-10-02
DE69019164T2 (de) 1995-09-07
SI20008A (sl) 2000-02-29
KR0158436B1 (ko) 1998-12-01
PL288271A1 (en) 1991-12-16
CN1036504C (zh) 1997-11-26
HUT64480A (en) 1994-01-28
FI19991917A7 (fi) 1999-09-09
CA2071811C (en) 2003-11-04
CN1055541A (zh) 1991-10-23
NO305275B1 (no) 1999-05-03
IL96676A (en) 1996-09-12
PL166035B1 (pl) 1995-03-31
NO307835B1 (no) 2000-06-05
CN1096516A (zh) 1994-12-21
IE68414B1 (en) 1996-06-12
HRP920872A2 (en) 1997-06-30
US5683699A (en) 1997-11-04
CA2071811A1 (en) 1991-06-15
ZA9010065B (en) 1992-02-26
NO973311L (no) 1992-08-14
ATE121947T1 (de) 1995-05-15

Similar Documents

Publication Publication Date Title
CN1049223C (zh) 改进的脑膜炎双球菌多糖结合菌苗
AU754890B2 (en) Enterococcus antigens and vaccines
JP4171068B2 (ja) 修飾したメニンゴコッカスのポリサッカライドを結合したワクチン
CN1159064C (zh) 甲型链球菌多糖免疫原性组合物及方法
JP2631035B2 (ja) 多糖類−タンパク質複合体
NZ281146A (en) Antigenic preparation of helicobacter bacteria lipopolysaccharide and its use in treating helicobacter infection
US20070010482A1 (en) Polysaccharide derivatives and uses in induction of an immune response
JPH06507494A (ja) 細菌性アレルゲンにより惹起される疾患の検出及び治療方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee